Medically reviewed by Elizabeth Barnes, RDN Key Takeaways GLP-1 drug use was associated with slightly higher risks of bone ...

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

The GPR133 receptor is expressed by osteoblasts, the cells that make bone. The study suggests that this receptor helps those cells sense two kinds of input: mechanical strain and signals relayed by ...

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...

Can an augmented health care delivery pathway reduce the chances of those future fractures and improve outcomes that are important to patients? Two University of Alabama at Birmingham researchers have ...

Many women on dialysis quickly developed severe hypocalcemia after starting denosumab (Prolia) for osteoporosis, Medicare data showed. During the first 12 weeks of treatment, 41.1% of women on ...

REYKJAVIK, ICELAND (July 20, 2022) – Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today ...

REYKJAVIK, Iceland, July 02, 2024 (GLOBE NEWSWIRE) -- Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today ...